Clinical Programs
Clinical program records track how obesity treatment assets move through development. They should connect sponsors, active ingredients, mechanisms, indications studied, trial records, development phases, endpoints, status changes, and regulatory plans when those relationships are publicly sourced.
This area is designed for dated, status-aware records rather than timeless summaries. Clinical development can change quickly, so program pages should preserve source context, jurisdiction where relevant, and the date associated with each material milestone.
Future clinical program coverage should help readers see how company pipelines, mechanisms, indications, and regulatory strategies relate to one another across the obesity treatment industry.
This is a starting clinical-program map, not a clinical-results comparison or treatment guide. Program records should avoid implying product superiority unless the comparison is explicitly supported, scoped, and sourced.
Semaglutide STEP program
Section titled “Semaglutide STEP program”The STEP program connects Novo Nordisk, semaglutide, and Wegovy’s product record. It is useful for mapping how a sponsor, GLP-1 active ingredient, branded product, and later regulatory milestones fit together across the obesity-treatment database.
Source: ClinicalTrials.gov STEP 1 record
The full SURMOUNT record separates pivotal adult studies, lifestyle-intervention and randomized-withdrawal designs, obstructive-sleep-apnea studies, active comparison, morbidity and mortality outcomes, and adolescent development. It connects tirzepatide, Zepbound, Eli Lilly, and GIP/GLP-1 receptor agonism without treating the program as one trial or one result.
Sources: SURMOUNT clinical-program record, ClinicalTrials.gov SURMOUNT-1 record
Liraglutide SCALE program
Section titled “Liraglutide SCALE program”The SCALE program connects liraglutide to obesity-related clinical development and to Saxenda’s place in the earlier GLP-1 obesity market. It is useful for tracing the relationship between an active ingredient, a branded obesity product, and the clinical evidence base that preceded regulatory records.
Source: ClinicalTrials.gov SCALE Obesity and Prediabetes record
CagriSema development records
Section titled “CagriSema development records”CagriSema connects Novo Nordisk, semaglutide, and cagrilintide in a fixed-dose combination-development program. Novo Nordisk submitted the asset for FDA review in December 2025; coverage should remain sponsor-, trial-, indication-, and date-specific unless a regulator grants market authorization.
Source: ClinicalTrials.gov CagriSema search
Retatrutide development records
Section titled “Retatrutide development records”Retatrutide is an investigational GIP, GLP-1, and glucagon receptor agonist in Eli Lilly’s phase 3 obesity pipeline. Lilly reported positive TRIUMPH-1 topline results in May 2026, but the asset remains unapproved as of July 23, 2026; trial design, full results, regulatory review, and product availability remain separate records.
Sources: ClinicalTrials.gov TRIUMPH-1 record, Lilly TRIUMPH-1 announcement, May 21, 2026
Orforglipron development records
Section titled “Orforglipron development records”Orforglipron moved from development into an approved US product record when FDA approved Eli Lilly’s Foundayo on April 1, 2026. The ATTAIN clinical program remains relevant to its evidence history, but Foundayo’s current label, oral formulation, approved population, and commercial status should no longer be described as merely development-stage.
Sources: FDA Foundayo approval notice, FDA Foundayo approval letter